Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024

Aprea Therapeutics, Inc.

2024-Q1 EPS reported -$0.67

Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.
Cash and equivalents $32.4M as of March 31, 2024, up from $21.6M at Dec 31, 2023; runway into Q3 2025.
FDA cleared IND for APR-1051 (WEE1 inhibitor) in March 2024; Phase 1 ACESOT-1051 trial expected to start June 2024.
Phase 1/2a ATRN-119 (ATR inhibitor) trial continues; dose escalation completion expected 4Q 2024; initial efficacy data possible 2H 2024.
Completed $16M upfront private placement in March 2024 with potential for additional $18M warrants; appointed Nadeem Mirza as CMO effective May 1, 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.